These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 36504559)

  • 1. Identification of VASH1 as a Potential Prognostic Biomarker of Lower-Grade Glioma by Quantitative Proteomics and Experimental Verification.
    Aili Y; Maimaitiming N; Maimaiti A; Liu W; Qin H; Ji W; Mahemuti Y; Wang Y; Wang Z
    J Oncol; 2022; 2022():2621969. PubMed ID: 36504559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNMT3A promotes glioma growth and malignancy via TNF-α/NF-κB signaling pathway.
    Su X; Liu J; Tu Z; Ji Q; Li J; Liu F
    Transl Cancer Res; 2024 Apr; 13(4):1786-1806. PubMed ID: 38737693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
    Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
    BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
    Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
    Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and validation of transferrin receptor protein 1 for predicting prognosis and immune infiltration in lower grade glioma.
    Wu H; He H; Huang J; Wang C; Dong Y; Lin R; Cheng Z; Qiu Q; Hong L
    Front Mol Neurosci; 2022; 15():972308. PubMed ID: 36483569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
    Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
    Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma.
    Chen X; Fu G; Li L; Zhao Q; Ke Z; Zhang R
    J Trace Elem Med Biol; 2022 Dec; 74():127082. PubMed ID: 36155420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma.
    Xiulin J; Wang C; Guo J; Wang C; Pan C; Nie Z
    Aging (Albany NY); 2022 Mar; 14(6):2819-2854. PubMed ID: 35349479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and validation of an individualized prognostic signature of lower-grade glioma based on nine immune related long non-coding RNA.
    Maimaiti A; Jiang L; Wang X; Shi X; Pei Y; Hao Y; Paerhati H; Zibibula Y; Abudujielili A; Kasimu M
    Clin Neurol Neurosurg; 2021 Feb; 201():106464. PubMed ID: 33454543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selenoprotein S (SELENOS) is a potential prognostic biomarker for brain lower grade glioma.
    Wang Y; Qu K; Xia Z; Qi M; Du X; Ke Z; Zhang R
    J Trace Elem Med Biol; 2024 Dec; 86():127539. PubMed ID: 39378668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated Analysis Reveals Prognostic Value and Immune Correlates of CD86 Expression in Lower Grade Glioma.
    Qiu H; Tian W; He Y; Li J; He C; Li Y; Liu N; Li J
    Front Oncol; 2021; 11():654350. PubMed ID: 33954112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated analysis of inflammatory response subtype-related signature to predict clinical outcomes, immune status and drug targets in lower-grade glioma.
    Cao Y; Zhu H; Chen Q; Huang H; Xie D; Li X; Jiang X; Ren C; Peng J
    Front Pharmacol; 2022; 13():914667. PubMed ID: 36091778
    [No Abstract]   [Full Text] [Related]  

  • 13. The combined signatures of telomere and immune cell landscape provide a prognostic and therapeutic biomarker in glioma.
    Han X; Yan Z; Fan K; Guan X; Hu B; Li X; Ou Y; Cui B; An L; Zhang Y; Gong J
    Front Immunol; 2023; 14():1220100. PubMed ID: 37662954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma.
    Zhang M; Wang X; Chen X; Zhang Q; Hong J
    Front Genet; 2020; 11():363. PubMed ID: 32351547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel Mitochondrial-Related Gene Signature for the Prediction of Prognosis and Therapeutic Efficacy in Lower-Grade Glioma.
    Yang J; Shen L; Zhou J; Wu J; Yue C; Wang T; Chai S; Cai Y; Xu D; Lei Y; Zhao J; Zhou Y; Mei Z; Xiong N
    Biochem Genet; 2024 Oct; ():. PubMed ID: 39356352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PLEKHA4 is a novel prognostic biomarker that reshapes the tumor microenvironment in lower-grade glioma.
    Zhi W; Wang Y; Jiang C; Gong Y; Chen Q; Mao X; Deng W; Zhao S
    Front Immunol; 2023; 14():1128244. PubMed ID: 37818357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma.
    Maimaiti A; Tuersunniyazi A; Meng X; Pei Y; Ji W; Feng Z; Jiang L; Wang Z; Kasimu M; Wang Y; Shi X
    Front Genet; 2022; 13():872186. PubMed ID: 35937991
    [No Abstract]   [Full Text] [Related]  

  • 18. Pan-cancer integrated bioinformatics analysis reveals cuproptosis related gene FDX1 is a potential prognostic and immunotherapeutic biomarker for lower-grade gliomas.
    Huang W; Wu Y; Zhu J; Luo N; Wang C; Liu S; Cheng Z
    Front Mol Biosci; 2023; 10():963639. PubMed ID: 36825202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of four immune-related genes in lower-grade gliomas: a biomarker discovery study.
    Wang S; Wang Z; Liu Z; Wu J
    Front Genet; 2024; 15():1403587. PubMed ID: 39192888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
    Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
    Front Immunol; 2022; 13():899710. PubMed ID: 35677036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.